GENE EDITING 101
All Companies
🇬🇧

Isomorphic Labs

Private

AI-first drug discovery from DeepMind

Isomorphic Labs, spun out of Google DeepMind, applies cutting-edge AI (including AlphaFold-derived models) to drug discovery. The company raised $600M in March 2025 and partners with major pharma companies including Eli Lilly and Novartis.

Founded2021
HQLondon, UK
CEODemis Hassabis
StatusPrivate
Total Funding$600M

Pipeline

Drug / ProgramIndicationPhaseTechnology
Undisclosed oncology programCancerPreclinicalAI-designed small molecules
Eli Lilly partnershipMultipleDiscoveryAI drug design
Novartis partnershipMultipleDiscoveryAI drug design

Key People

Demis HassabisCEO (also CEO of Google DeepMind)
Max JaderbergCOO

Related Articles

Every Longevity Biotech Company You Should Know in 2026
Longevity Science
Market Analysis

Every Longevity Biotech Company You Should Know in 2026

From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.

Mar 25, 20268 min read